These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15138675)

  • 1. Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme.
    Lagneau F; Perbet S; Delefosse D; Wernet A; Stocco J; Marty J
    Intensive Care Med; 2004 Jun; 30(6):1247. PubMed ID: 15138675
    [No Abstract]   [Full Text] [Related]  

  • 2. Which oral valproic acid formulation is best for my patient?
    Knox JE; Freeland KN
    JAAPA; 2015 Jan; 28(1):21-3. PubMed ID: 25522023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-equivalence of bioavailability between generic and branded form of sodium valproate.
    Dhanaraj M; Jayavelu A
    Neurol India; 2004 Sep; 52(3):398. PubMed ID: 15472447
    [No Abstract]   [Full Text] [Related]  

  • 4. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

  • 5. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers.
    Cawello W; Bonn R
    J Clin Pharmacol; 2012 Nov; 52(11):1739-48. PubMed ID: 22162508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pharmacokinetic optimization of depakin in children with epilepsy].
    Shamansurov ShSh
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(6):37-8. PubMed ID: 7740873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid for Kleine-Levin syndrome.
    Crumley FE
    J Am Acad Child Adolesc Psychiatry; 1997 Jul; 36(7):868-9. PubMed ID: 9204661
    [No Abstract]   [Full Text] [Related]  

  • 8. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
    Van Matre ET; Cook AM
    Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of an oral loading dose of divalproex sodium during acute alcohol withdrawal.
    Reoux JP; Saxon AJ; Shen D
    J Clin Psychopharmacol; 2006 Feb; 26(1):105-7. PubMed ID: 16415725
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate.
    Genton P
    Acta Neurol Scand Suppl; 2005; 182():26-32. PubMed ID: 16359430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
    Sherr JD; Kelly DL
    Psychiatr Serv; 1998 Oct; 49(10):1355-7. PubMed ID: 9779912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Valproic acid serum through concentrations estimated from 12 hours post-dose concentrations in patients treated with Depakine® Crono].
    Lampón N; Tutor JC
    Farm Hosp; 2013; 37(1):79-80. PubMed ID: 23461508
    [No Abstract]   [Full Text] [Related]  

  • 13. Circadian variation of Valproic acid pharmacokinetics in mice.
    Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA
    Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy.
    Juárez-Olguín H; Lugo-Goytia G; Flores-Murrieta F; Ruiz-García M; Lares Asseff I; Flores Pérez J
    Rev Invest Clin; 2010; 62(6):516-23. PubMed ID: 21416779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
    Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
    Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cholestyramine resin on single dose valproate pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Diskin CJ
    Int J Clin Pharmacol Ther; 1996 May; 34(5):208-11. PubMed ID: 8738857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients.
    Methaneethorn J; Lohitnavy M
    Eur J Hosp Pharm; 2020 May; 27(3):168-172. PubMed ID: 32419938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.